Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2004-12-13
2008-12-23
Hartley, Michael G. (Department: 1618)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
C424S400000, C424S404000
Reexamination Certificate
active
07468391
ABSTRACT:
The invention provides methods for treating an individual having a retinoid responsive disorder. In one embodiment, a method involves administering to the individual an effective amount of a selective CYP26B inhibitor, the selective CYP26B inhibitor having at least 10-fold selectivity for CYP26B relative to CYP26A. In another embodiment, a method involves administering to the individual an effective amount of a selective CYP26A inhibitor, the selective CYP26A inhibitor having a chemical formula set forth in the specification. The invention further provides screening methods for identifying a selective CYP26A inhibitor or selective CYP26B inhibitor.
REFERENCES:
patent: 5648503 (1997-07-01), Vuligonda et al.
patent: 5723666 (1998-03-01), Vuligonda et al.
patent: 5952345 (1999-09-01), Klein et al.
patent: 6252090 (2001-06-01), Vasudevan et al.
patent: 6303785 (2001-10-01), Vasudevan et al.
patent: 6313107 (2001-11-01), Vasudevan et al.
patent: 6359135 (2002-03-01), Vasudevan et al.
patent: 6380256 (2002-04-01), Vasudevan et al.
patent: 6387892 (2002-05-01), Vasudevan et al.
patent: 6387951 (2002-05-01), Vasudevan et al.
patent: 6399774 (2002-06-01), Vasudevan et al.
patent: 6495552 (2002-12-01), Vasudevan et al.
patent: 6531599 (2003-03-01), Vasudevan et al.
patent: 2002/0132796 (2002-09-01), Vasudevan et al.
patent: 2003/0166932 (2003-09-01), Beard et al.
patent: WO 01/44443 (2001-06-01), None
patent: WO 02/48334 (2002-06-01), None
patent: WO 03/072769 (2003-09-01), None
patent: WO 2005/007631 (2005-01-01), None
Johnson, Jl et al. “Relationship between drug activity in NCI preclinical in vitro and in vivo models and early clinical trails”, British Journal of Cancer, 84(10, p. 1424-1431, 2001.
Talmadge, et al. “Murine Models to Evaluate Novel and Conventional Strategies for Cancer”, American Journal of Pathology, 170(3), p. 793-804, 2007.
“Prevent”; from dictionary.com accessed Nov. 28, 2007.
Thacher, et al., “Therapeutic Applications for Ligands of Retinoid Receptors,”Current Pharm. Design6:25-58 (2000).
Kuijpers, et al., “The effects of oral liarozole on epidermal proliferation and differentiation in severe plaque psoriasis are comparable with those of acitretin,”British Journal of Dermatology139:380-389 (1998).
Bollag, et al., “Retinoids in cancer prevention and therapy,”Ann. Ocol. 3:513-526 (1992).
Chiesa, et al., “Prevention of Local Relapses and New Localisations of Oral Leukoplakias with the Synthetic Retinoid Fenretinide (4-HPR). Preliminary Results,”Oral Oncol., Eur. J. Cancer28(B):97-102 (1992).
Costa, et al., “Prospects of Chemoprevention of Human Cancers with the Synthetic Retinoid Fenretinide,”Cancer Res. 54:Supp. 54:2032s-2037s (1994).
Verma, “Inhibition of Both Stage I and Stage II Mouse Skin Tumor Promotion by Retinoic Acid and the Dependence of Inhibition of Tumor Promotion on the Duration of Retinoic Treatment,”Cancer Res. 47:5097-5101 (1987).
Lippman, et al., “13-cis-Retinoic Acid and Interferon alpha-2a: Effective Combination Therapy for Advanced Squamous Cell Carcinoma of the Skin,”J. Natl. Cancer Inst. 84:235-241 (1992) Text only, no table or figures.
Lippman, et al., “13-cis-Retinoic Acid Plus Interferon alpha-2a: Highly Active Systemic Therapy for Squamous Cell Carcinoma of the Cervix,”J. Natl. Cancer Inst. 84:241-245 (1992) Text only, no table or figures.
Bonhomme, et al., “Topical treatment of epidemic kaposi's sarcoma with all-trans-retinoic acid,”Ann. Oncol. 2:234-235 (1991).
Huang, et al., “Use of All-TransRetinoic Acid in the Treatment of Acute Promyelocytic Leukemia,”Blood72:567-572 (1988).
Castaigne, et al., “All-Trans Retinoic Acid as a Differentiation Therapy for Acute Promyelocytic Leukemia. I. Clinical Results,”Blood76:1704-1709 (1990).
Lo Coco, et al., “Molecular Evaluation of Response to All-Trans-Retinoic Acid Therapy in Patients With Acute Promyelocytic Leukemia,”Blood77(8):1657-1659 (1991).
Warrell, et al., Differentiation Therapy of Acute Promyelogytic Leukemia with Tretinoin (All-)(Trans)-Retinoic Acid)N. Engl. J. Med.324:1385-1393 (1991).
Chomienne, et al., “Retinoid differentiation therapy in promyelocytic leukemia,”FASEB J. 10: 1025-1030 (1996).
Conner, et al., “Retinoic Acid Synthesis in Normal and Alzheimer Diseased Brain and Human Neural Cells,”Mol. Chem. Neuropathol. 30(3):239-252 (1997).
Goodman and Pardee, “Evidence for defective retinoid transport and function in late onset Alzheimer's disease,”Proc. Natl. Acad. Sci. USA, 100(5):2901-2905 (2003).
Carelli, et al., “Optic nerve degeneration and mitochondrial dysfunction: genetic and acquired optic neuropathies,”Neurochem. Intl. 40:573-584 (2002).
Olichon, et al., “Loss of OPA1 Perturbates the Mitochondrial Inner Membrane Structure and Integrity, Leading to CytochromecRelease and Apoptosis,”J. Biol. Chem. 278(10):7743-7746 (2003).
Massaro and Massaro, “Retinoic acid treatment abrogates elastase-induced pulmonary emphysema in rats,”Nature Medicine3:675-677 (1997).
Ray, et al., “CYP26, a Novel Mammalian Cytochrome P450, Is Induced by Retinoic Acid and Defines a New Family,”J. Biol. Chem. 272 (30):18702-18708 (1997).
Loudig, Olivier, et al., “Cytochrome P450RAI(CYP26) Promoter: A Distinct Composite Retinoic Acid Response Element Underlies the Complex Regulation of Retinoic Acid Metabolism,”Mol. Endocrinology, 14(9):1483-1497 (2000).
White, et al., “Identification of the human cytochrome P450, P450RAI-2, which is predominantly expressed in the adult cerebellum and is responsible for all-trans-retinoic acid metabolism,”Proc. Natl. Acad. Sci. USA97(12):6403-6408 (2000).
White, et al., “cDNA Cloning of Huma Retinoic Acid-metabolizing Enzyme (hP450RAI) Identifies a Novel Family of Cytochromes P450 (CYP26),”J. Biol. Chem. 272(30):18538-18541 (1997).
Abu-Abed, Suzan, S., “Mouse P40RAI (CYP26) Expression and Retinoic Acid-inducible Retinoic Acid Metabolism in F9 Cells Are Regulated by Retinoic Acid Receptor γ and Retinoid X Receptor α,”J. Biol. Chem., 273(4):2409-2415 (1998).
Bligh, et al., “A Rapid Method of Total Lipid Extraction and Purification,”Canadian Journal of Biochemistry and Physiology, 37(8):911-917 (1959).
Moore, et al., “Homogenous repair of nuclear genes after experimental stroke,”J. Neurochem. 80:111-118 (2002).
Akasu, et al., “Hyperexcitability of hippocampal CA1 neurons after fluid percussion injury of the rat cerebral cortex,”Neurosci. Lett. 329:305-308 (2002).
Scheifer, et al., “Rats with chronic spinal cord transection as a possible model for the at-level pain of paraplegic patients,”Neurosci. Lett. 323:117-120 (2002).
Lewis, et al., “Animal modelss of retinal detachment and reattachment: identifying cellular events that may affect visual recovery,”Eye16:375-387 (2002).
Chen, et al., “An Animal Model for Lung Volume Reduction Therapy of Pulmonary Emphysema,”J. Invest Surg11:129-137 (1998).
Barlaam, et al., “New α-Substituted Succinate-Based Hydroxamic Acid as TNFα Convertase Inhibitors,”J.Med.Chem., 42:4890-4908 (1999).
Floyd, et al., “Cyclic Analog of Ethacrynic Acid,”Journal of Pharmaceutival Sciences, 59(6):869-870 (1970).
Teng, et al., “Identification of a Retinoic Acid receptor α Subtype Specific Agonist,”Journal of Medicinal Chemistry, 39(16):3035-3038 (1996).
Beard Richard
Bhat Smita
Chandraratna Roshantha A.
Li Ling
Liu Xiaoxia
Allergan Inc.
Hamilton Brook Smith & Reynolds P.C.
Hartley Michael G.
Westerberg Nissa M
LandOfFree
Methods for treating retinoid responsive disorders using... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating retinoid responsive disorders using..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating retinoid responsive disorders using... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4027678